Wells Fargo & Company Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS) had its price objective reduced by stock analysts at Wells Fargo & Company from $28.00 to $26.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 129.28% from the stock’s current price.

A number of other analysts also recently commented on the company. Jefferies Financial Group started coverage on Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating for the company. Wedbush lowered Keros Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $47.00 to $15.00 in a research note on Friday, January 17th. TD Cowen downgraded shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Piper Sandler reduced their price target on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a research report on Friday, January 17th. Finally, Oppenheimer decreased their price objective on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research note on Thursday, January 16th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.33.

Keros Therapeutics Stock Performance

NASDAQ KROS traded up $0.40 during trading hours on Thursday, hitting $11.34. 373,085 shares of the company’s stock were exchanged, compared to its average volume of 1,593,696. The business’s 50 day moving average is $12.76 and its 200-day moving average is $39.99. Keros Therapeutics has a 12-month low of $9.77 and a 12-month high of $73.00. The firm has a market capitalization of $459.35 million, a P/E ratio of -2.18 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. The firm had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. As a group, equities research analysts anticipate that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Trading of Keros Therapeutics

Several large investors have recently modified their holdings of the business. TFG Asset Management GP Ltd purchased a new position in Keros Therapeutics in the fourth quarter valued at about $1,630,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Keros Therapeutics by 27.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 64,416 shares of the company’s stock valued at $1,020,000 after buying an additional 13,864 shares during the last quarter. Twinbeech Capital LP grew its position in shares of Keros Therapeutics by 742.5% during the fourth quarter. Twinbeech Capital LP now owns 129,553 shares of the company’s stock worth $2,051,000 after buying an additional 114,175 shares in the last quarter. Two Sigma Advisers LP increased its stake in shares of Keros Therapeutics by 200.0% in the fourth quarter. Two Sigma Advisers LP now owns 20,700 shares of the company’s stock worth $328,000 after buying an additional 13,800 shares during the last quarter. Finally, Two Sigma Investments LP raised its holdings in Keros Therapeutics by 226.1% in the fourth quarter. Two Sigma Investments LP now owns 33,664 shares of the company’s stock valued at $533,000 after acquiring an additional 23,342 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.